Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV program-driven stock growth.
7 Biotech Stocks to Buy for Their Game-Changing Potential Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024 DTIL stock results show that Precision BioSciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023 DTIL stock results show that Precision BioSciences missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Earnings Scheduled For March 27, 2024 Companies Reporting Before The Bell • Local Bounti (
NYSE:LOCL ) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
SPX, Nasdaq Look To Continue Rally Fresh off a fourth-straight monthly win on Wall Street, stocks are on the rise as the week winds down.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!
Why Precision BioSciences Stock Is Up Today Precision BioSciences, Inc. (
NASDAQ: DTIL ) shares are trading higher Tuesday after the company announced it has signed a licensing agreement wit
